256 related articles for article (PubMed ID: 17316592)
1. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis.
Coste TC; Armand M; Lebacq J; Lebecque P; Wallemacq P; Leal T
Clin Biochem; 2007 May; 40(8):511-20. PubMed ID: 17316592
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis.
Al-Turkmani MR; Freedman SD; Laposata M
Prostaglandins Leukot Essent Fatty Acids; 2007; 77(5-6):309-18. PubMed ID: 18036797
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study.
Lloyd-Still JD; Powers CA; Hoffman DR; Boyd-Trull K; Lester LA; Benisek DC; Arterburn LM
Nutrition; 2006 Jan; 22(1):36-46. PubMed ID: 16226012
[TBL] [Abstract][Full Text] [Related]
4. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis.
Jumpsen JA; Brown NE; Thomson AB; Paul Man SF; Goh YK; Ma D; Clandinin MT
J Cyst Fibros; 2006 May; 5(2):77-84. PubMed ID: 16507353
[TBL] [Abstract][Full Text] [Related]
5. Circulating fatty acid profiles in response to three levels of dietary omega-3 fatty acid supplementation in horses.
King SS; Abughazaleh AA; Webel SK; Jones KL
J Anim Sci; 2008 May; 86(5):1114-23. PubMed ID: 18192545
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis.
Olveira G; Olveira C; Acosta E; Espíldora F; Garrido-Sánchez L; García-Escobar E; Rojo-Martínez G; Gonzalo M; Soriguer F
Arch Bronconeumol; 2010 Feb; 46(2):70-7. PubMed ID: 20045240
[TBL] [Abstract][Full Text] [Related]
7. Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients.
Van Biervliet S; Devos M; Delhaye T; Van Biervliet JP; Robberecht E; Christophe A
Prostaglandins Leukot Essent Fatty Acids; 2008 Feb; 78(2):109-15. PubMed ID: 18276127
[TBL] [Abstract][Full Text] [Related]
8. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial.
Panchaud A; Sauty A; Kernen Y; Decosterd LA; Buclin T; Boulat O; Hug C; Pilet M; Roulet M
Clin Nutr; 2006 Jun; 25(3):418-27. PubMed ID: 16325968
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent.
Hogg RJ; Fitzgibbons L; Atkins C; Nardelli N; Bay RC;
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1167-72. PubMed ID: 17699343
[TBL] [Abstract][Full Text] [Related]
10. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
McKenney JM; Sica D
Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
[TBL] [Abstract][Full Text] [Related]
11. Toward optimizing vision and cognition in term infants by dietary docosahexaenoic and arachidonic acid supplementation: a review of randomized controlled trials.
Hoffman DR; Boettcher JA; Diersen-Schade DA
Prostaglandins Leukot Essent Fatty Acids; 2009; 81(2-3):151-8. PubMed ID: 19505812
[TBL] [Abstract][Full Text] [Related]
12. Functional effects of increasing omega-3 fatty acid intake.
Carlson SE
J Pediatr; 1997 Aug; 131(2):173-5. PubMed ID: 9290597
[No Abstract] [Full Text] [Related]
13. Role of n-3 fatty acids in prevention of disease complications in patients with HIV.
Woods MN
Nutr Clin Care; 2005; 8(1):24-30. PubMed ID: 15850231
[TBL] [Abstract][Full Text] [Related]
14. Docosahexaenoic acid (DHA) and cardiovascular disease risk factors.
Holub BJ
Prostaglandins Leukot Essent Fatty Acids; 2009; 81(2-3):199-204. PubMed ID: 19545988
[TBL] [Abstract][Full Text] [Related]
15. Is there a case for n-3 fatty acid supplementation in cystic fibrosis?
Cawood AL; Carroll MP; Wootton SA; Calder PC
Curr Opin Clin Nutr Metab Care; 2005 Mar; 8(2):153-9. PubMed ID: 15716793
[TBL] [Abstract][Full Text] [Related]
16. alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans.
Brenna JT; Salem N; Sinclair AJ; Cunnane SC;
Prostaglandins Leukot Essent Fatty Acids; 2009; 80(2-3):85-91. PubMed ID: 19269799
[TBL] [Abstract][Full Text] [Related]
17. The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters.
Bryhn M; Hansteen H; Schanche T; Aakre SE
Prostaglandins Leukot Essent Fatty Acids; 2006 Jul; 75(1):19-24. PubMed ID: 16806871
[TBL] [Abstract][Full Text] [Related]
18. Complementary therapies in cystic fibrosis: nutritional supplements and herbal products.
Braga SF; Almgren MM
J Pharm Pract; 2013 Feb; 26(1):14-7. PubMed ID: 23178411
[TBL] [Abstract][Full Text] [Related]
19. Docosahexaenoic acid (DHA), a primary tumor suppressive omega-3 fatty acid, inhibits growth of colorectal cancer independent of p53 mutational status.
Kato T; Kolenic N; Pardini RS
Nutr Cancer; 2007; 58(2):178-87. PubMed ID: 17640164
[TBL] [Abstract][Full Text] [Related]
20. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis.
Keen C; Olin AC; Eriksson S; Ekman A; Lindblad A; Basu S; Beermann C; Strandvik B
J Pediatr Gastroenterol Nutr; 2010 May; 50(5):537-44. PubMed ID: 20639712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
